Innovation

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine […]

10 July 2024 Innovate UK has awarded four UK companies a share of £4 million funding through Contracts for Innovation to support innovative research into dementia diagnosis. The funding will enable organisations to evaluate blood-based and digital biomarkers as part of the Bio-Hermes-002 study. This international study is led by the Global Alzheimer’s Platform Foundation® […]

The Washington, D.C.-based Global Alzheimer’s Platform Foundation announced on July 8 that Snellville resident Tamiko MaGee-Rodgers has been named director of the foundation’s Recruitment and Strategic Initiatives. The nonprofit GAP was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research and lowering the cost and duration of […]

Washington D.C., July 8, 2024- Global Alzheimer’s Platform Foundation® (GAP) announced the appointment of Leigh Zisko, MPH as Chief Impact Officer and Tamiko MaGee-Rodgers, PhD, CCRP as the Director of Recruitment and Strategic Initiatives. In newly created global leadership roles, each will meaningfully contribute new perspectives and experience to GAP’s work in innovating clinical trial […]

Washington D.C., July 2, 2024- Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer applauds the U.S. Food and Drug Administration (FDA) for its decision granting full traditional approval of Eli Lilly and Company’s Kisunla™ (donanemab), a disease-modifying Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD).  “Today, the FDA grants full approval for donanemab, […]

Washington D.C., July 1, 2024- The Food and Drug Administration (FDA) unveiled a draft guidance document, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” which is open for public comment. This draft guidance points to improving participation from people who are traditionally underrepresented in clinical trials. John Dwyer, President […]

Resident contributor, Dr. Susan Steen breaks down three life changes to trackto prioritize your brain health as you and your loved ones age. As people age, it’s normal to experience occasional forgetfulness, however when does ‘some’ memory loss become a bigger concern? There are three aspects of your life that you can reflect on and […]

Global non-profit expands research network to the greater New Orleans areato improve access to research opportunities Washington D.C., June. 17, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming its first clinical research site from Louisiana into its network, Tandem Clinical Research of greater New Orleans. Tandem Clinical Research, a Prolerity Clinical Research Company site, advances […]

Washington D.C., June. 14, 2024- Global Alzheimer’s Platform Foundation® (GAP) proudly collaborated with The Global CEO Initiative on Alzheimer’s Disease (CEOi) to release the peer-reviewed publication of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease,” in Nature Reviews Neurology. Alzheimer’s blood tests have the […]

Washington D.C., June.10, 2024- Global Alzheimer’s Platform Foundation® (GAP) –applauds the U.S. Food and Drug Administration (FDA)’s acceptance of Eisai’s application for the subcutaneous maintenance dosing of Leqembi. With an action date set for January 25, 2025, this autoinjector will be used for weekly maintenance dosing and stands to reduce the burden on patients who are eligible to receive this disease-modifying therapy, as it can be used […]

Global Alzheimer’s Platform Foundation 2023 National Citizen Scientist Champion Award recipient Jeannie Weiss and Syrentis Clinical Research Vice President/Director of Clinical Operations Dr. Lorrie Bisesi join to discuss Alzheimer’s #octalkradio

Support from Scottish Parliament Underscores Its Significance Washington D.C., May 30, 2024-  The Global Alzheimer’s Platform Foundation® (GAP)  and the Scottish Funding Council’s Brain Health ARC have announced swift progress in the next steps of the Bio-Hermes Biomarker Data Challenge 2024, the research competition using the most comprehensive set of dementia biomarker data from ground-breaking […]

In the hands of the SFC-funded Brain Health ARC, the Bio-Hermes dataset offers the Scottish dementia research community a platform for new ideas, collaboration and early career development. Millie Mather explains more in our latest guest blog. During my working hours, I can be identified as the sole person in the room without a PhD in science or medicine. In fact, […]

Costa Mesa resident Jeannie Weiss is driving Alzheimer’s research forward and is receiving a national award for her exemplary volunteerism to help advance science. The Global Alzheimer’s Platform Foundation (GAP) recognized Weiss for her exceptional role in Alzheimer’s research. Weiss received GAP’s 2023 National Citizen Scientist Champion Award, which is given to individuals who act […]

28th March 2024 Scotland has been selected to host a first-of-its-kind Alzheimer’s research competition, representing ‘significant recognition of the country’s wealth of world-leading expertise,’ says the Chief Scientist for Health Professor Anna Dominiczak welcomed the news that Scotland has already launched the Bio-Hermes Biomarker Data Challenge, granting access to what has been called “the most comprehensive […]

The Global Alzheimer’s Platform Foundation® (GAP) has announced that Scotland will host the Bio-Hermes Biomarker Data Challenge 2024, a groundbreaking research competition utilizing the most extensive collection of dementia biomarker data from innovative early blood testing studies for Alzheimer’s disease. Researchers at the Universities of Glasgow and St. Andrews, under the auspices of the Scottish […]

Washington D.C., Mar. 25, 2024- The Global Alzheimer’s Platform Foundation® (GAP) – which is focused on global game-changing dementia research – has chosen Scotland to host the Bio-Hermes Biomarker Data Challenge 2024, a research competition using the most comprehensive set of dementia biomarker data from ground-breaking early blood testing studies for Alzheimer’s disease. Researchers at […]

POSTED ON MARCH 19, 2024BY CHRIS YOUNG It’s estimated over 580 thousand Floridians are living with Alzheimer’s disease. A study could lead to a simpler way to detect the disease. The study, called Bio-Hermes, showed how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time. Currently, scans or spinal taps […]

08 Mar 2024 ANALYSIS by Cathy Kelly; catherine.kelly@citeline.comExecutive Summary Donanemab’s review delay will create more distance from Lilly’s direct-to-consumer advertising spotlighting its commitment to Alzheimer’s research. The company has also been supporting development of blood-based tools for early diagnoses, though they would not eliminate PET scans. Eli Lilly and Company launched unbranded direct-to-consumer TV advertising […]

By Katharine Lang on March 4, 2024 — Fact checked by Amanda WardA simple blood test, may in the future, help diagnose Alzheimer’s early. Image credit: Oleksii Syrotkin/Stocksy. Dementia currently affects around 60 millionTrusted Source people worldwide, and the number is projected to rise to more than 150 million by 2050. Alzheimer’s disease, the most common form of dementia, causes 60-80% of cases. Available treatments […]

Oral Presentation on Bio-Hermes to Take Place at Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD) Washington D.C., Mar 04, 2024- Global Alzheimer’s Platform Foundation®, (GAP) is pleased to share that new data from the ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, will be shared by Douglas Beauregard, Project Director of Clinical Operations […]

LabPulse.com staff writers Mar 1, 2024The first results from the Bio-Hermes study have been released, showing a strong correlation between several blood-based and digital biomarkers with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer’s disease (AD). The findings from the study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, show […]

By LabMedica International staff writersPosted on 29 Feb 2024      Alzheimer’s disease, which traditionally requires costly scans or invasive spinal taps for diagnosis, is now closer to being more easily identified through innovative blood tests. This advancement is particularly crucial with the recent approval of disease-modifying treatments for Alzheimer’s. Now, the results of a study […]

Feb 28, 2024 | Jessica Kim Cohen NEW YORK – Results from blood-based biomarker tests correlated with the presence of beta-amyloid detected using established Alzheimer’s disease diagnostics, according to a study published Wednesday. PET scans and cerebrospinal fluid (CSF) analyses are highly accurate and established methods of identifying elevated levels of beta-amyloid, a hallmark of Alzheimer’s. However, these […]